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Topic Relevance by Timeline

Summary
Some healthcare laws affect academic entrepreneurs who may also be practicing healthcare
providers. Understanding the regulatory agencies and relevant laws is essential to avoiding
legal entanglement with regulatory authorities and creating a successful health business
venture.
● It is important to follow ethical standards in starting and managing a company. Ethical
shortcuts may yield short-term benefits but pose substantial risk in the long run, including the
potential for ethical and financial malfeasance.
●

Introduction
According to one study, major contributors to increasing healthcare costs are fraud and abuse; in
2009, fraud and abuse associated with wasteful healthcare represented approximately 3%–10% of
healthcare costs (Price and Norris). The government is committed to law enforcement with
healthcare-specific legislation. Combating fraud and abuse imposes additional costs for law enforcement and physician oversight.
While one may believe that the behavior of entrepreneurs who do not follow the law is rooted in a
weak moral compass, the truth is a bit more complicated. Lapses in following the law are often
rooted in lack of awareness of the regulations or the implications of not following them (Krause).
Some entrepreneurs believe “moral shortcuts” in entrepreneurship are a tool necessary for their
company’s survival. For others, these shortcuts are a rite of passage and considered proof of their
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grit in the “fake it till you make it” culture of some entrepreneurship communities. The consequences of law breaking, regardless of whether it is by commission or omission, may destroy
careers. In this chapter, we will explore some of the healthcare laws that academic entrepreneurs
should be familiar with. We will also discuss one case in which an entrepreneur’s immoral behaviors, though intended to sustain the business, ultimately led to its downfall.

Challenges Facing the Academic Entrepreneur
The typical entrepreneur’s goal is to maximize the commercial potential in the shortest possible
time without getting “scooped” by a competitor. Many academic entrepreneurs carry on with their
faculty/staff/student roles while innovating and developing ideas. In the health entrepreneurship
space, some play the role of healthcare provider and business entrepreneur simultaneously. Academic medical institutions have compliance offices to guide academics in how to manage these
dual roles legally. However, as these institutions are large and complex, it is incumbent upon the
academic entrepreneur to have an awareness of key statutes and agencies that regulate these issues
and to maintain an awareness of what planned or current entrepreneurial activities might be covered by regulations.

Agencies Involved in Regulating Healthcare
As an academic entrepreneur, one may have to deal with multiple agencies that will ultimately
reimburse for or purchase the invented goods and services. It is ideal to forge a successful partnership with them at the outset. The main healthcare agencies and what they regulate are included
below.

Department of Health and Human Services (HHS)

The HHS (www.hhs.gov) is responsible for the regulation of interstate medical issues and administration of health services in the country. Further, the HHS delegates the approval and regulation
of pharmaceuticals and devices (through the Food and Drug Administration) and the administration of the Medicare and Medicaid programs (along with the individual state governments) through
the Centers for Medicare and Medicaid Services (CMS).

Food and Drug Administration (FDA)

The FDA (www.fda.gov) is responsible for ensuring that human and veterinary drugs, and vaccines and other biological products and medical devices intended for human use, are safe and
effective before approval. Generally, these products require FDA approval before they can be sold
in the United States. The FDA will consider efficacy and side effects of a product (often from
studies provided by the manufacturer) prior to approval. The FDA has an Office of Criminal
Investigations (“FDA-OCI” or “OCI”), which investigates crimes involving the production and
sale of food and drugs. It is not uncommon for medical entrepreneurs whose innovations include
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novel drug molecules (including biologics) or new devices that revolutionize medical treatment to
have significant interaction with the FDA for approval of newer technologies (see the chapters
“Overview of Device Development” and “Overview of Drug Development”).

Center for Medicare and Medicaid Services (CMS)

The CMS (www.cms.gov) administers Medicare and works with states to enable them to administer Medicaid. The CMS develops billing codes that cover a vast range of potential medical
procedures and treatments so that providers billing the government under these programs can
indicate what type of work or service was performed and receive reimbursement. Every year, over
$1 trillion is administered by the CMS (Verma). Fraud against the CMS is most commonly investigated by the Department of Health and Human Services Office of Inspector General (HHS-OIG).
The largest client (buyer of healthcare) in the healthcare industry is the CMS, and thus it is very
likely that academic entrepreneurs and their startups would have significant dealing with this
federal agency if their innovations translate into healthcare products (drugs or devices).

National Institutes of Health (NIH)

The NIH (www.nih.gov) funds a variety of scientific research across medical fields through
research conducted at NIH facilities and through the provision of grants to researchers outside of
government. The NIH is a major source of funding for academic entrepreneurs for early research
before more substantial funding is secured through private sources.

Overview of Healthcare Laws Relevant to Medical
Entrepreneurs
Some of the healthcare laws that entrepreneurs must keep in mind are listed below (this list is not
all-inclusive; academic entrepreneurs are advised to carefully research additional local regulations)
(Fleps):

Stark Law

Example: A successful business venture provides medical services or devices for treatment. If
patients are referred by the entrepreneur’s physician spouse to the business venture or to any medical provider who provides the new service, they may have violated the Stark Law, unless that
service falls within one of the statute’s exceptions.
The Stark Law (42 U.S.C. 1395nn, “Limitation on Certain Physician Referrals”), also known as
the Ethics in Patient Referrals Act, has one basic intent: to prohibit practitioners from referring
Medicare or Medicaid patients to any designated health service with which either they or their
immediate family members have a direct or indirect financial arrangement. It applies to doctors of
medicine, osteopathy, dental medicine, dental surgery, podiatry, optometry, and chiropractic medicine. The financial relationship in question can involve an exchange of cash, services in kind, or
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any other item or element of value. Originally enacted in 1989, expanded in 1993, and entering a
third phase in 2007, this so-called self-referral ban applies regardless of whether the designated
health services in question are themselves Medicare- or Medicaid-related.
The law restricts referrals to such designated health service categories as clinical laboratories,
physical therapists, occupational therapists, speech and language therapists, radiation therapists,
and radiology and imaging laboratories. It also covers non-coded categories such as hospital services, durable medical supplies like prosthetic or orthotic devices, home health providers, and
outpatient prescription medications. Since the Stark Law is a strict liability law (i.e., compliance
is mandatory), one could violate it without meaning to do so. Therefore, regardless of intentionality, sanctions and penalties will still apply.
Penalties for violation of the Stark Law include:
● Disallowing any entity that has furnished designated health services subsequent to a forbidden referral from billing Medicare, Medicaid, the patient, or a third-party provider.
● Compelling the designated health services provider to refund any monies received as the
result of a disallowed referral.
● Denying payment by Medicare or Medicaid for designated health services performed in
violation of Stark Law regulations.
● Imposing civil penalties of up to $24,478 for each claim submitted in defiance of the Stark
Law (Medicare Fraud and Abuse: Prevent, Detect, Report).
● Enforcing fines as high as $100,000 for those who engage in circumvention schemes to
make an end run around the law’s provisions (Medicare Fraud and Abuse: Prevent, Detect,
Report).
● Excluding offenders from future participation in Medicare and Medicaid programs.
Stark Law exceptions: The statute lists exceptions to the Stark Law for such categories as office
space or equipment rental, ownership of publicly traded mutual funds and securities, physician
recruitment, prepaid health plans, referrals to academic medical centers, and bona fide employment
agreements.

Anti-Kickback Statute

Example: An academic entrepreneur has devised a new valve that can be used for cardiac surgery.
They offer to take a local cardiac surgeon (who implants these devices at their hospital) for an
expensive dinner and pay the surgeon as a “consultant.” The entrepreneur may have violated the
Anti-Kickback Statute.
The federal Anti-Kickback Statute (42 U.S.C. 1320a-7b(b)), passed by Congress in 1972, is a
criminal statute that prohibits the exchange of (or offer to exchange) anything of value in an effort
to induce (or reward) the referral of federal healthcare program business. This broadly drafted
statute establishes penalties for individuals and entities on both sides of the prohibited transaction.
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For medical entrepreneurs, there can be no material incentive (financial or otherwise) placed for
increasing sales when federal healthcare dollars are involved. In short, under the “one purpose”
test, “if one purpose of the payment was to induce future referrals, the [M]edicare statute has been
violated” (“United States v. Greber, 760 F.2d 68”).
Penalties for violation of the Anti-Kickback Statute: Conviction for a single violation under the
Anti-Kickback Statute may result in a fine of up to $100,000 and imprisonment for up to five years
(Medicare Fraud and Abuse: Prevent, Detect, Report). In addition, conviction may result in exclusion from participation in federal healthcare programs. Absent a conviction, individuals who
violate the Anti-Kickback Statute may still face exclusion from federal healthcare programs at the
discretion of the Secretary of Health and Human Services. The government may also assess civil
money penalties, which could result in treble damages plus $50,000 for each violation of the AntiKickback Statute (Office of Inspector General, Department of Health and Human Services).
“Safe harbor” regulations exempt certain practices from being treated as Anti-Kickback Statute
violations. Safe harbors address the following types of arrangements: investment interests, space
rental, equipment rental, personal services and management contracts, sale of practice, referral
services, warranties, discounts, employees, and group purchasing organizations. The HHS and
CMS are in the process of revising the safe harbors to enable better innovation in the medical
community.

False Claims Act

Example: During initial trials, the innovation of a new biologic molecule has a 50% cure rate for
a disease. The academic entrepreneur exaggerates this success as 70% to improve the sales of the
drug, and CMS is one of the clients buying the drug for use by Medicare patients. The entrepreneur
has violated the False Claims Act and is liable.
Under the False Claims Act (31 U.S.C. 3729 – 3733), any person who knowingly presents a false
or fraudulent claim for payment or approval, knowingly makes a false record or statement material
to a false or fraudulent claim, or conspires to commit a violation of the above, is liable to the United
States government.
The term “knowingly” means that a person has actual knowledge, acts in deliberate ignorance of
the truth or falsity of the information, or acts in reckless disregard of the truth or falsity of the
information. The statute does not require proof of specific intent to defraud.
Penalties for violation of the False Claims Act: Conviction may result in a civil penalty of up to
$29,927, plus three times the amount of damages that the government sustains because of the false
claim (Medicare Fraud and Abuse: Prevent, Detect, Report). The defrauding entity may also be
barred from participating in CMS programs for a significant period of time, which often amounts
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to a death sentence for some innovators. Additionally, a criminal False Claims Act (18 U.S.C. 287)
allows for additional fines and imprisonment for those convicted of violations.

Academic Entrepreneurs: Mental State and Liability
Within the framework of the above regulations, it is important to keep in mind that most fraud and
abuse crimes have two basic elements: the act or the crime and the mental state or a culpability
requirement (Fleps). The culpability required varies by offense, and many possible offenses have
different culpability levels and different punishments. For example, false claim submissions to a
federal health program by a device manufacturer can happen in many ways. One false claim might
result from a simple oversight of the paperwork, which typically would be considered “negligent.”
If the entrepreneur willfully neglected responsibility, this would increase the severity of the crime
and typically be considered “reckless.” Of course, intentionally misleading claims would increase
culpability.
The various states of culpability include:
● Specific Intent: The defendant acted with a specified purpose and was aware of the surrounding circumstances that would enable their intended outcome. There was a conscious
effort to commit the specific fraud.
● General Intent: The defendant meant for the action or fraud to occur, but may not have
been aware of specific surrounding circumstances and may not have intended the result. A
common example of this might be an entrepreneur’s exaggeration of device capabilities
without a specific intent to mislead a customer.
● Knowledge: The entrepreneur knew that a certain device or drug would not work for a
certain situation, was practically certain what would happen with a high probability, but
continued to promote its use in the specific condition. This includes willful blindness,
which is when a defendant is aware of a high probability of a particular thing but intentionally ignores the facts. Often “knowingly” is coupled with “intentionally” disjunctively; in
other words, many crimes punish someone who knowingly or intentionally committed an
offense.
● Recklessness: The defendant knew their action could cause harm (though with less than
near certainty) and did it anyway. This involves a conscious disregard of substantial and
unjustifiable risk or a gross deviation from the normal standard of conduct that a law-abiding person would observe in the defendant’s situation.
● Negligence: The defendant did not know their action would cause harm, but an ordinary
person would have been aware of such a fact and taken care to avoid such an action. For
particularly tragic examples, think of the number of firearms-related deaths each year from
guns that were thought to be unloaded (but weren’t) or firearms left easily accessible to
small children.
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● Strict Liability: Even if the defendant took every precaution possible, they are responsible
for the resulting harm. Strict liability offenses are uncommon in criminal law, and they
typically result when an individual undertakes a potentially dangerous or hazardous activity. Device and pharmaceutical manufacturing and distribution offenses are strict liability.
Undisclosed drug or treatment side effects and device malfunction may be classified under
strict liability, and medical entrepreneurs may need insurance to avoid litigation and expensive settlements. Strict liability offenses are extremely powerful tools, because mental
state is no defense. A defendant may have taken reasonable—even exceptional—care and
not wanted the outcome at all but still be guilty of a strict liability offense. These rules vary
by state, but courts are often hesitant to impose a strict liability requirement in criminal
matters because of the extreme consequences of such liability

Ethics of Entrepreneurship
Moral Shortcuts

Moral shortcuts are procedures that simplify one’s workflow while eschewing conventional moral
paradigms (Timmons). For example, ignoring regulatory deadlines or intentionally modifying
study incentives to obtain greater participation without obtaining institutional review board approval may be forms of moral shortcuts that may seem to render the work process more efficient.
While these shortcuts may work in the short term, they pose a risk to the overall success when
exposed.
Rarely do entrepreneurs engage in blatantly unethical behaviors from the initiation of their company. On the contrary, immorality often starts with a moral shortcut. Time, funding, and
competitors all weigh on entrepreneurs, who strive to meet the most important deadlines, maintain
their company’s cash flows, and outplay the competition. In other words, the environment of the
academic entrepreneur inspires the decisions that are classifiable as “unethical.” As a consequence,
many ethical people find themselves in situations that could lead to unethical behavior.
Former federal prosecutor Serina Vash had this to say on the subject: “When I first began prosecuting corruption, I expected to walk into rooms and find the vilest people. I was shocked to find
ordinarily good people I could well have had coffee with that morning. And they were still good
people who’d made terrible choices” (Carucci). These decisions likely seemed not only acceptable
but also necessary to these “good people,” given their environment and circumstances. When academic entrepreneurs feel the burden of sustaining a business, moral shortcuts may suit their
immediate needs—so they take the shortcuts. Enter precedent.
Precedent is, according to the Oxford Dictionary, “[a]n earlier event or action that is regarded as
an example or guide to be considered in subsequent similar circumstances” (“Precedent | Meaning
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of Precedent by Lexico”). A moral shortcut is most likely and most frequently used when a company is fragile, and generally a company is at its most fragile when it is young. As the company
grows, it will continue experiencing obstacles that it is forced to overcome. Executives adapt the
company to these obstacles by considering the following question: “How have we handled situations like these before to get us as far along as we are now?”
Companies using conventional morality and companies using moral shortcuts both establish a
precedent that will be institutionalized in their history. Executives of a conventionally moral company will practice conventional moral behaviors when adapting to their circumstances, whereas
the executives of a morally ambiguous company might defend themselves thus: “We did nothing
wrong; we simply made a smart decision that kept this company alive.” But now they have fewer
reservations because they have already established that the decision that was considered morally
unconventional yesterday is considered morally acceptable today. The bar has been lowered, and
their perception of ethically acceptable behavior has become more inclusive.
Figure 1. Two Sides Relating Moral Shortcuts.

Elizabeth Holmes and Theranos
Before achieving notoriety for its immense scandal, Theranos was the epitome of MedTech
startups. Its founders were innovators who took personal risks (such as dropping out of Stanford)
to start a company that would fundamentally shift a healthcare paradigm and disrupt the healthcare
industry. One cofounder, Elizabeth Holmes, was frequently compared to another controversial innovator, Steve Jobs. The company promised an incredible product—equipment for laboratory
blood testing with minimal sample requirements—and appeared to be delivering both on finances
and technological development. When the dream ended and the many faults of Theranos emerged,
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the public was left confused. Perhaps a better understanding can be gained by viewing Theranos
not as a demonized company but as a startup that had made “questionable business decisions,
which in totality create[d] a desperate situation” (Polisi).
When the preliminary results were unsatisfactory, there were two primary choices for Theranos:
inform the investors and risk losing funding (thereby risking the company becoming financially
insolvent) or withhold the information from investors on the chance that later success would cause
“all … [to] be forgiven” (Polisi). Theranos chose the latter approach. This early decision of omission had a cascading effect.
Eventually, investors will wish to know not only that financial projections are positive but also
that the technology works. According to former Theranos employee Doug Matje, when he worked
there, Theranos could not complete any test accurately on their devices (O’Donnell). Holmes was
ultimately charged with nine counts of wire fraud and two counts of conspiracy to commit wire
fraud (Mangan).
From a distance, we can tell that the strategy used by the leaders of Theranos was problematic. But
in a high-stakes environment where every weakness can prove fatal, it is not surprising that non–
risk-averse entrepreneurs will take those risks. This is why the most crucial lesson is that entrepreneurship relies on careful decision-making and consideration of the associated risks, both in terms
of the immediate present and future consequences. Seemingly inconsequential decisions can have
cascading effects that can lead to substantial ethical lapses in the future. Seeking counsel from
others, relying on objective data, and being aware of innate biases are important ways to mitigate
this (see the chapters on “Conducting Insightful Market Research” and “Innate Biases”).

Conclusion
This chapter outlines some of the legal and ethical responsibilities of medical entrepreneurs and
needs to be reviewed periodically as laws governing healthcare change. Dramatic moral and ethical situations can arise when one is facing challenging financial situations (e.g., for early startups).
These situations are an opportunity for an organization’s leaders to demonstrate the wisdom and
judgment they wish to codify in their company culture. In addition, key legal considerations include the Anti-Kickback Statute, the False Claims Act, and the Stark Law.
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